Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib

Figure 4

Axial CT chest with contrast approximately 3 months later in an outpatient follow-up, demonstrating a marked improvement of her infiltrate.